Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Altimmune typically reports earnings after market close, meaning Day 0 reflects anticipation and any after-hours reaction, while Day +1 captures the first full trading session following the release.

Altimmune's post-earnings price action has been volatile and directionally mixed. On average, the stock has moved 9.47% in absolute terms on earnings day (Day 0), with a wide range of 13.71%. The most dramatic move came in November 2024, when the stock surged 29.12% on Day 0—likely tied to positive clinical data or a major pipeline update. More recently, moves have been more subdued: the stock fell 2.33% on Day 0 following the August 2026 Q2 report, despite beating estimates, and declined 1.95% in May 2026 after the Q1 beat.

Day +1 follow-through has been more muted, averaging 2.32% with a range of 8.46%. This suggests that initial reactions tend to be sharp but often fade or reverse in the following session. The March 2026 report was an outlier, with a 17.92% decline on Day 0 followed by a modest 1.00% gain on Day +1, indicating a significant negative surprise that took time to stabilize.

For the upcoming report, investors should expect heightened volatility given the company's transition to Phase 3 and the recent AUD data. Any updates on PERFORMA enrollment, regulatory feedback on AUD, or changes to the cash runway guidance could drive outsized moves.

Part 2.2: Options Market Expected Move

The options market is pricing a 7.25% expected move for the November 6 weekly expiration, implying a range of $1.96 to $2.26. This is below the stock's average historical Day 0 move of 9.47%, suggesting options traders may be underpricing near-term volatility. Given the company's recent clinical milestones and the potential for material updates on trial execution or regulatory strategy, the actual move could exceed the options-implied range. Traders positioning for earnings should consider that the historical range has been as wide as 13.71%, and the stock has demonstrated the capacity for double-digit swings on major catalysts.

Part 3: What Analysts Are Saying

Altimmune has a Strong Buy consensus from analysts, with 9 Strong Buy ratings, 0 Moderate Buy ratings, and 3 Hold ratings. There are no Sell ratings. The average recommendation score is 4.50, reflecting strong bullish sentiment. This consensus has been unchanged over the past month, indicating stable conviction among the analyst community.

The average price target is $14.50, with a high estimate of $28.00 and a low of $2.50. At the current price of $2.12, the consensus target implies upside of approximately 584%, reflecting analysts' view that pemvidutide's multi-indication potential is significantly undervalued at current levels. The wide range of targets—from $2.50 to $28.00—underscores the binary nature of clinical-stage biotech investing: success in PERFORMA and AUD could drive substantial appreciation, while setbacks could pressure the stock toward the low end of the range.

The unchanged sentiment over the past month suggests analysts are waiting for the next set of catalysts—likely this earnings report, updates on PERFORMA enrollment, or regulatory feedback on AUD—before revising their views. The Strong Buy consensus reflects confidence in the clinical data to date, the company's cash position, and the market opportunity in MASH and alcohol-related liver diseases, but also acknowledges the execution risk inherent in late-stage trials.

Part 4: Technical Picture

The Barchart Technical Opinion for Altimmune is currently 100% Sell, up from 100% Sell last week and 48% Sell a month ago. The signal has strengthened significantly, moving from a moderate Sell to a unanimous bearish reading. The trend is described as Strong and Strengthening, indicating deteriorating technical momentum heading into the earnings release.

Timeframe Analysis:

• Short-term (100% Sell): The near-term technical picture is decisively bearish, with all short-term indicators pointing to downside pressure. This suggests the stock is facing immediate headwinds and may struggle to gain traction in the days surrounding the report.

• Medium-term (100% Sell): The intermediate timeframe also shows a unanimous Sell signal, indicating that the weakness is not just a short-term phenomenon but reflects a broader loss of momentum over the past several weeks.

• Long-term (100% Sell): Even the longer-term trend has turned fully bearish, suggesting that the stock's technical foundation has eroded across all timeframes. This is a notable shift from the 48% Sell reading a month ago, indicating accelerating downside momentum.

Trend Characteristics: The Strong and Strengthening trend environment suggests that bearish momentum is building and could persist into the earnings event. This technical setup implies that the stock may need a significant positive catalyst—such as a major earnings beat, bullish guidance, or a transformative partnership announcement—to reverse the current downtrend.

The stock is currently trading at $2.12, below all major moving averages. It is above the 5-day ($2.07) and 10-day ($2.08) moving averages, suggesting a very short-term bounce, but below the 20-day ($2.23), 50-day ($2.76), 100-day ($2.86), and 200-day ($3.25) moving averages. This configuration indicates that while the stock has stabilized in the very near term, it remains in a longer-term downtrend and is trading well below its intermediate and long-term trend lines.

The distance from the 200-day moving average is particularly notable—the stock is more than 34% below that level, reflecting sustained selling pressure over the past several months. The technical setup heading into earnings is cautionary: the stock is oversold on a longer-term basis, which could set up a relief rally if results are better than feared, but the lack of support from moving averages suggests limited technical cushion if the report disappoints. Investors should watch for a break above the 20-day moving average ($2.23) as a sign that momentum is shifting, or a failure to hold the 5-day and 10-day averages as a signal that the downtrend is resuming.